Boehringer Ingelheim recently announced it will tighten its 340B contract pharmacy restrictions by requiring claims data submission.

BI Tightens Contract Pharmacy Restrictions for All Covered Entities

November 5, 2024 William Newton, Editor-in-Chief 340B Report Views

Drugmaker Boehringer Ingelheim (BI) will begin requiring all 340B covered entities to submit claims data to continue accessing 340B drugs [...]

Please Login or Become a Paid Subscriber to View this Content

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!